论文部分内容阅读
Eucrisa是由美国安纳考尔医药公司研制的用于治疗特应性皮炎的软膏剂,2016年12月14日FDA批准其用于轻度至中度特应皮炎的外用治疗。Eucrisa的活性成分Crisaborole是磷酸二酯酶-4抑制剂,是一种含硼的小分子抗炎药,其作用机制尚未完全明确。临床研究表明,Crisaborole的疗效明显,29 d对轻至中度特应性皮炎患者的平均治愈可达到32%,且安全性高,对2岁及以上儿童和怀孕期妇女未见不良影响。Crisaborole是美国FDA在过去15年首次批准治疗特应性皮炎的新药,为特异性皮炎患者提供了一种重要的非类固醇替代疗法。笔者就该药的基本信息、作用机制、药动学、药效学、临床试验及应用等研发动态进行了概述,以期能为医院临床用药起到指导作用。
Eucrisa is an ointment for the treatment of atopic dermatitis developed by Amcorc Pharmaceuticals, USA. On December 14, 2016, the FDA approved its topical treatment for mild to moderate atopic dermatitis. The active ingredient of Eucrisa Crisaborole is a phosphodiesterase-4 inhibitor, is a small molecule anti-inflammatory drug containing boron, the mechanism of action is not yet completely clear. Clinical studies have shown that Crisaborole has a significant therapeutic effect, with a mean cure rate of 32% for patients with mild-to-moderate atopic dermatitis at 29 days, which is safe and has no adverse effect on children aged 2 years and over and pregnant women. Crisaborole, the new drug approved by the U.S. FDA for atopic dermatitis for the first time in 15 years, provides an important alternative to nonsteroidal replacement therapy for patients with atopic dermatitis. The author of the drug’s basic information, mechanism of action, pharmacokinetics, pharmacodynamics, clinical trials and application developments such as R & D overview, in order to play a guiding role for the clinical use of the hospital.